The Medical Device Revenue Trap—and the One Move That Gets You Out

I've spent 25 years building revenue organizations. I've scaled past $3 billion, led teams of more than 200 people, and served as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. I run PULSE RevOps and the free revenue tools on this site.

And I've seen the same painful script play out in a dozen medical device companies: the product clears regulatory hurdles, the founder breathes a sigh of relief, and then... Nothing scales.

You don't need a full-time Chief Revenue Officer. Not yet. You need a fractional CRO—and I'm going to tell you exactly why, exactly when, and exactly how to know if you're the CEO who needs to make that call today.

The Signal You Can't Afford to Ignore

Here's the truth: your medical device company needs a fractional CRO when your commercial engine has outgrown founder-led or rep-led selling but cannot yet justify a full-time CRO at $300,000 to $500,000 a year plus equity. The clearest signal in this industry is specific: you have a cleared or approved product and a sales team in the field, but your long, multi-stakeholder sales cycles are unpredictable, nobody owns the full revenue system across direct reps, independent distributors, and clinical adoption, and your forecast is a guess that your board no longer trusts.

A fractional CRO gives you that senior revenue leadership a few days a month, for a fraction of the cost, with none of the hiring risk.

If you're the founder or CEO still personally closing the marquee accounts, or you have a VP of Sales who can manage reps but cannot architect the territory model, the distributor strategy, and the value-analysis-committee playbook underneath them—you are the exact situation a fractional CRO is built for.

Medical device revenue is its own animal. Buying decisions run through surgeons, supply chain, and value analysis committees. Reimbursement shapes demand.

The gap between regulatory clearance and real commercial traction is where many promising companies stall. You do not need another full-time executive on payroll. You need someone who has built and scaled revenue organizations for two decades to come in, diagnose what is actually breaking your commercialization, build the system, and hand it to your team to run.

The 7 Signs It's Time—Be Brutally Honest

If three or more of these are true, it's time to have the conversation:

1. You have clearance but commercial traction is stalling. The product is cleared or approved and a few champion accounts love it, but revenue is not scaling the way the regulatory milestone promised, and you cannot explain the gap.
2. The founder or CEO is still closing the big accounts. The commercial engine lives in your relationships and your head, not in a system your reps and distributors can run without you. The company cannot scale past its founder.
3. Nobody owns the full revenue system. Direct reps, independent distributors, marketing, clinical education, and customer success each optimize their own piece, and the handoffs leak. No single leader is accountable for revenue end to end.
4. Your distributor strategy is improvised. You signed distributors opportunistically, terms vary deal to deal, and no one has modeled where direct selling beats distribution or how to manage channel conflict and distributor performance against quota.
5. Sales cycles are long and the forecast is fiction. Deals move through surgeons, supply chain, and value analysis committees over many months, close dates slip every quarter, and your board no longer believes the pipeline number.
6. Your comp and territory design fight your goals. Territories were drawn by geography rather than opportunity, and the comp plan rewards reps for the easy reorder instead of the harder new-account or full-portfolio sale that drives durable growth.
7. You cannot afford—or do not need—a full-time CRO. The role would cost $300K to $500K all-in, and a venture-stage or early-commercial device company rarely has twelve months of full-time CRO work to justify it.

What a Fractional CRO Actually Does (Spoiler: It's Not Coaching)

A fractional CRO is not a coach who gives advice and leaves. They take ownership of the revenue engine on a part-time basis—typically a few days a month on a fixed monthly retainer—and build the system that runs when they are not there. In a device company, that work is shaped by long sales cycles, mixed channels, and clinical buyers.

Diagnose first. Before changing anything, a good fractional CRO audits the real numbers: pipeline by stage and by account, win rates, true sales-cycle length through the value analysis committee, rep ramp time, direct-versus-distributor economics, territory coverage against opportunity, comp performance, and the gross profit each product line and channel actually produces.

Most founders are surprised by what surfaces in the first two weeks—especially how much revenue is concentrated in a few champion surgeons.

Install the operating system. Then they build the pieces that make device revenue predictable: a territory model drawn around opportunity rather than geography, a direct-versus-distributor strategy with clear rules and quota accountability, a value-analysis-committee and clinical-adoption playbook reps can actually run, a comp plan that drives new accounts and the full portfolio, and a stage-based forecast that respects long cycles while giving the board a number it can trust.

Align the whole commercial team. Sales, clinical education, marketing, and customer success start chasing the same goals, measured the same way, so the handoff from clearance to trial to adoption to reorder stops leaking.

Hand it off. The goal is not to make you dependent. A fractional CRO trains your VP of Sales and regional managers to run the territory, distributor, and forecasting systems, so the engine keeps producing after the engagement winds down.

The Three Roles—and Why You're Probably Hiring the Wrong One

These three roles are not interchangeable, and hiring the wrong one is expensive.

• VP of Sales manages and motivates the field team. They run the reps and distributors day to day, but most do not architect the territory model, the channel strategy, the value-analysis-committee playbook, or the cross-functional alignment from clearance to adoption. If your reps are capable but your *commercial system* is broken, a VP will not fix it.
• Full-time CRO owns all of revenue and is the right answer once you are large enough to keep a $300K-to-$500K executive busy and accountable full time—usually past meaningful commercial scale with a broad portfolio and a large field and distributor network.
• Fractional CRO gives you that same senior, system-level leadership before you can justify the full-time cost—a few days a month, a fixed retainer, and no equity or severance risk. It is the bridge that gets you from founder-closed deals and an improvised channel to a real, repeatable commercial engine.

What the First 90 Days Actually Looks Like

A good fractional CRO engagement is structured, not open-ended. In the first 30 days, the focus is diagnosis: a deep read of pipeline by account and stage, true sales-cycle length, direct-versus-distributor economics, territory coverage, comp performance, and per-product gross profit, plus interviews with your sales leaders, a handful of reps, and key distributors.

By day 30, you get a written commercial assessment with the three biggest gaps and the plan to fix them.

Days 31 to 60 are about building: the territory model, distributor rules of engagement, the value-analysis-committee playbook, a comp plan that drives the right behavior, and a forecasting cadence that ends the fiction. The fractional CRO runs the weekly revenue review and holds your commercial leaders accountable to the new system.

Days 61 to 90 are about turning the keys over. Your VP of Sales and regional managers learn to run the system themselves. The fractional CRO steps back to an advisory cadence—monthly check-ins and quarterly deep dives—while you own the engine.

Why I'm the Operator You Want in the Room

Medical device commercialization lives or dies on disciplined, large-scale field execution—and that is the kind of revenue organization I have actually run. Scaling revenue past $3 billion and leading teams of more than 200 across a distributed, quota-carrying field force at Cellular Sales meant building exactly the muscles a device company needs: territory design that puts reps where the volume is, ramp programs that get new hires productive fast in a complex sale, comp plans that drive the full product line rather than the one easy SKU, and forecasting discipline rigorous enough to stand up to scrutiny.

I bring that operating rigor to the device-specific problems—direct-versus-distributor mix, value-analysis-committee navigation, and the long path from clearance to adoption—without the cost or commitment of a full-time executive.

For a device company stuck between regulatory approval and real revenue, that is precisely the operator to have in the room.

Here's the bottom line: You don't need to hire another executive. You need someone who has built the numbers they advise on, who will diagnose what's actually breaking your commercialization, build the system, and hand it to your team to run. That's what I do through CRO Syndicate —a network of senior revenue practitioners who have actually built the numbers they advise on, and the fastest way to find a vetted fractional CRO near you.

👉 See me on LinkedIn or check out the free revenue tools at PULSE RevOps. Stop guessing. Start scaling.

*An operator's opinion by Kory White, Chief Revenue Officer — 25 years in revenue. More at PULSE · CRO Syndicate*